title: Controlled release of drugs from injectable in situ formed biodegradable PLGA microspheres: effect of various formulation variables.
abstract: A novel in situ method for the preparation of injectable biodegradable poly(lactide-co-glycolide) (PLGA) microspheres for the controlled delivery of drugs is described here. A stable dispersion of PLGA microglobules ('premicrospheres' or 'embryonic microspheres') in a vehicle mixture on injection, comes in contact with water from aqueous buffer or physiological fluid, thereby hardening the microglobules into solid matrix type microparticles entrapping the drug (in situ formed microspheres). The drug is then released from these microspheres in a controlled fashion. The effect of the following formulation variables on the characteristics of the novel drug delivery system (NDDS) was investigated: (i) the concentrations of polyethylene glycol 400 (PEG 400), the encapsulated drug, and the hydrophilic excipient (mannitol); and (ii) the types of encapsulated drug (micromolecules and macromolecules such as protein) and vehicles (replacing triacetin and Miglyol 812 by triethyl citrate and soybean oil respectively). Also, the effect of formulation, process, and storage (15 days/4 degrees C) conditions on the physical stability of the encapsulated protein was evaluated. The in vitro drug release was enhanced with decrease in the PEG 400 concentration and increase in the drug and mannitol concentration. The drug release was retarded with increase in the molecular weight of the encapsulated drug. Substitution of triacetin by triethyl citrate and miglyol 812 by soybean oil resulted in variation in the release of the drug from the in situ formed microspheres. A preliminary investigation of the physical stability of the myoglobin revealed that the alpha-helical structure was unaffected by the formulation, process, and the storage conditions.
authors.affiliation: Department of Applied Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI 02881, USA. rjain@elancorp.com
authors.forename: R A
authors.initials: RA
authors.lastname: Jain
authors.forename: C T
authors.initials: CT
authors.lastname: Rhodes
authors.forename: A M
authors.initials: AM
authors.lastname: Railkar
authors.forename: A W
authors.initials: AW
authors.lastname: Malick
authors.forename: N H
authors.initials: NH
authors.lastname: Shah
mesh_terms: D002626:Chemistry, Pharmaceutical; D016503:Drug Delivery Systems; D007267:Injections; D019344:Lactic Acid / Q000008:administration & dosage*; D008353:Mannitol / Q000008:administration & dosage; D008863:Microspheres; D014677:Pharmaceutical Vehicles; D011092:Polyethylene Glycols / Q000008:administration & dosage; D011100:Polyglycolic Acid / Q000008:administration & dosage*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000008:administration & dosage*
chemical_list: D014677:Pharmaceutical Vehicles; D011108:Polymers; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D008353:Mannitol; D011092:Polyethylene Glycols